Reverse phase protein array is a high-throughput technology that performs protein assays on thousands of samples simultaneously, including tissue and cell lysates, serum, plasma or other body fluids.
Registry expected to pair Ignite's reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for ...
Evaluation of BRCA1/2 mutation status among women with triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its ...
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies (THER), Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase ...
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite ...
RICHMOND, VIRGINIA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- The Virginia Innovation Partnership Corporation (VIPC) today announced that George Mason ...
The registry is designed to pair Ignite’s CLIA-certified Reverse Phase Protein Array (“RPPA”) platform with structured clinical outcomes tracking to evaluate the real-world utility of functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results